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Abstract
Background: Licensed antiviral therapeutics and vaccines to protect against eastern equine encephalitis virus
(EEEV) in humans currently do not exist. Animal models that faithfully recapitulate the clinical characteristics of
human EEEV encephalitic disease, including fever, drowsiness, anorexia, and neurological signs such as seizures, are
needed to satisfy requirements of the Food and Drug Administration (FDA) for clinical product licensing under the
Animal Rule.
Methods: In an effort to meet this requirement, we estimated the median lethal dose and described the
pathogenesis of aerosolized EEEV in the common marmoset (Callithrix jacchus). Five marmosets were exposed to
aerosolized EEEV FL93-939 in doses ranging from 2.4 × 101 PFU to 7.95 × 105 PFU.
Results: The median lethal dose was estimated to be 2.05 × 102 PFU. Lethality was observed as early as day 4 post-
exposure in the highest-dosed marmoset but animals at lower inhaled doses had a protracted disease course
where humane study endpoint was not met until as late as day 19 post-exposure. Clinical signs were observed as
early as 3 to 4 days post-exposure, including fever, ruffled fur, decreased grooming, and leukocytosis. Clinical signs
increased in severity as disease progressed to include decreased body weight, subdued behavior, tremors, and lack
of balance. Fever was observed as early as day 2–3 post-exposure in the highest dose groups and hypothermia was
observed in several cases as animals became moribund. Infectious virus was found in several key tissues, including
brain, liver, kidney, and several lymph nodes. Clinical hematology results included early neutrophilia, lymphopenia,
and thrombocytopenia. Key pathological changes included meningoencephalitis and retinitis.
Immunohistochemical staining for viral antigen was positive in the brain, retina, and lymph nodes. More intense
and widespread IHC labeling occurred with increased aerosol dose.
Conclusion: We have estimated the medial lethal dose of aerosolized EEEV and described the pathology of clinical
disease in the marmoset model. The results demonstrate that the marmoset is an animal model suitable for
emulation of human EEEV disease in the development of medical countermeasures.
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Background
New world alphaviruses such as Eastern equine encephalitis
virus (EEEV) are the cause of highly pathogenic disease that
can manifest as severe encephalitis in humans. Due to high
infectivity, ability to induce devastating disease, ease of pro-
duction, high degree of stability, and the potential for aero-
solization, EEEV is considered a potential biological threat
agent against both the Warfighter and civilians and is classi-
fied as a category B pathogen by the CDC and NIAID [1].
EEEV is a single-stranded, positive-sense RNA virus found
in the eastern half of North America [2]. The disease is zoo-
notic in humans and severe infection can result in neuro-
logical invasion and encephalitis with mortality rates
ranging from 33–70% [3, 4]. Encephalitic patients often ex-
perience severe symptoms of disease including high fever,
headache, vomiting, general or focal seizures, focal weak-
ness, cranial nerve palsies, and coma; long-term neuro-
logical sequelae may persist in survivors (~25%) and can
include both motor and cognitive impairments [4–6]. EEEV
is also pathogenic for equines and can produce mortality
rates as high as 80–90% in horses [2]. Long-term neuro-
logical sequelae are observed in about 66% of surviving
equines [2]. Until recently, EEEV was considered to consist
of four genetic lineages [7]. Lineage I was considered to be
the North American (NA) variant of EEEV, while lineages
II, III and IV were the South American (SA) variants. The
latter three lineages have now been classified as a new viral
species, Madariaga virus [7]. EEEV strains (previously re-
ferred to as NA strains) are transmitted by the mosquito
vector and are prevalent in coastal and swampy regions of
the eastern United States; between 2003 through 2012, 89
cases of EEEV were confirmed in the US [3]. The geograph-
ical range of EEEV infections stretched from the Gulf to At-
lantic coasts, with the majority of cases reported from
Florida, Massachusetts, Alabama, North Carolina, New
Hampshire, Louisiana, and Georgia [3].
The need for licensed vaccines and antiviral therapeutics
for human use in the event of EEEV infection has fostered
research efforts to characterize multiple animal models
that can be used to assess efficacy of novel countermea-
sures, with respect to FDA guidance on the development
of products under the Animal Rule [8]. Marmosets are a
species of nonhuman primates (NHP) used in a wide
range of research efforts for human disease such as repro-
ductive biology, behavioral research, and biomedical re-
search [9, 10]. Marmosets have previously been used to
assess intranasal EEEV infection [11]. The small size of
the marmoset allows for easy handling, reasonable hous-
ing space, and provides greater amounts of test material
for research than traditional rodent models. The ease of
breeding in captivity coupled with the fact that the num-
bers of animals in the wild are not threatened represent
additional considerations for the justification and use of
this species in biomedical research [11, 12]. However, in
spite of previous use of the marmoset as a model of intra-
nasal EEEV infection, there remains a need to understand
how aerosol infection affects the host, as the aerosol route
has been proposed to be the most likely route of infection
used in a potential bioterrorism event. It is conceivable
that aerosol exposure, may produce a different disease
course, pathology, or disease outcome from the intranasal
exposure [13, 14]. Infections generated by aerosol inhal-
ation may produce different pathology and infection kinet-
ics because aerosolized particles deposit deep within the
alveolar spaces of the lung. Indeed, experimental evidence
of EEEV infection in mice and human challenge models of
Adenovirus infection demonstrate the variable effects on
disease development and pathology that can be observed
depending on the exposure route in both mice and
humans [15, 16].
Cynomolgus macaques (cynos) have previously been
used to model EEEV aerosol infection [17] using the
EEEV FL91-4679 strain. In aerosol simulations, the cyno
model has been shown to recapitulate many of the clin-
ical signs of human infection, such as fever, seizures, and
leukocytosis; however, other signs including increased
liver enzymes and serum indicators of liver damage have
not been observed in humans and suggest that while the
cyno is a good model for some parameters, there is
much that we do not understand about the pathology of
the disease in different models. In addition to potentially
disparate disease responses in the cyno in comparison to
humans, the animals are becoming increasingly difficult
and expensive to obtain for medical research [12, 18]. As
an alternate nonhuman primate model, marmosets offer
several distinct advantages over the traditional macaque
model including the fact that marmosets do not harbor
herpes B virus, breed well in captivity but are also abun-
dant in the wild, and their small body size translates to
decreased amounts of compound for drug testing or
vaccine development [12].
The study design of the experiments described herein
employed a staircase or up-and-down protocol to esti-
mate the median lethal dose in marmosets wherein the
marmosets were exposed to a range of aerosolized EEEV
FL93-939 doses and followed for clinical disease and
course of pathogenesis of EEEV disease. This assessment
is critical for the development of the marmoset as an
animal model that can potentially mimic human disease
and to compare the responses in the marmoset to other
animal models of EEEV disease following aerosol infec-
tion (e.g., cynomolgus macaques). We describe the dif-
ferential effects of dose on the immune cell populations
in the blood, blood chemistry, viral burden in tissue,
fever, body weight, and changes in blood oxygen satur-
ation levels as part of the clinical symptoms and path-
ology. These results, particularly the differential dose
effects of aerosolized EEEV on fever, virus dissemination,
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neurological signs, and hematological parameters, reveal
that the common marmoset is a promising model of le-
thal inhalational EEEV infection for use in the develop-
ment of medical countermeasures.
Methods
Animals
Five healthy, adult common marmosets (Callithrix jac-
chus) (1 male, 4 females) were obtained from the United
States Army Medical Research Institute of Infectious
Diseases (USAMRIID) nonhuman primate colony and
randomly assigned for exposure order. All marmosets
were determined to be naïve to previous alphavirus in-
fection and to be free of common opportunistic patho-
gens to include lymphocytic choriomeningitis virus
(LCMV) Salmonella, Shigella, Campylobacter, and Kleb-
siella pneumoniae. All marmosets were sexually mature
adults, ranged between 290 and 375 g in weight and
were between 2 and 4 years of age at the time of study
[18]. A mixture of male and female marmosets was used
following FDA Animal Rule guidelines and the animals
were at both the age and weight to be consistent with
prime-age and size adults [8, 12, 18]. Using prime-aged,
healthy adult animals was important to the characterization
of the marmoset as a model of EEEV-induced encephalitis
as these studies are ultimately intended to provide support
of medical countermeasure development for the Warfigh-
ter. Marmosets were given water ad libitum, received the
customary marmoset diet twice daily, daily dietary enrich-
ment consisting of fresh fruit or yogurt, as well as conven-
tional environmental enrichment including a mirror,
nesting box, and perch bar. Animals were surgically im-
planted with subcutaneous Data Sciences International
(DSI) TA-F40 telemetry implants to remotely monitor
temperature. Approximately one week prior to aerosol
exposure, animals were moved to biosafety level-3 (BSL-3)
facilities at USAMRIID and housed in cages that were
modified for marmosets. The animals were housed in
rooms that were maintained at approximately 25 °C and on
a 12 h light/dark cycle.
Virus
The FL93-939 strain is a prototype North American
EEEV strain. It was originally isolated from a pool of
mosquitoes (Culiseta melanura) from Florida in 1993.
The virus was a kind gift from Dr. Scott Weaver, Univer-
sity of Texas Medical Branch. The virus isolate history
included one passage through C6/36 mosquito cells, one
passage in suckling mouse brain, one passage in Vero
cells (derived from African Green monkey kidney cells),
and one passage in baby hamster kidney (BHK) cells at
USAMRIID to produce the sucrose-purified stock. The
passage history of the viral isolate may be important to
understanding the virulence of the strain or potential
adaptation for infection in humans or equines. Purified
virus was diluted to the appropriate concentration in
unsupplemented Eagle’s Modified Essential Medium
with non-essential amino acids (EMEM w/NEAA) prior
to aerosol exposure.
Aerosol challenge
In preparation for aerosol challenge, marmosets were
initially anesthetized with inhaled isoflurane and main-
tained with Ketamine-Acepromazine (Ket-Ace) during
the aerosol exposure procedure. Each marmoset was ex-
posed to aerosolized EEEV in a head-only exposure
chamber contained in a class III biological safety cabinet
inside a BSL-3 laboratory. Aerosol exposure was con-
trolled and monitored using the Automated Bioaerosol
Exposure system (ABES) [19]. Delivery of the target
aerosol dose relied upon calculations of minute volume
based on Guyton’s formula, taking into consideration:
(1) the flow to volume ratio of the exposure chamber,
(2) the starting EEEV concentration in the Collison
nebulizer, and (3) the spray factor calculated from sham
experiments using the virus stock [20]. All exposures
were generated with a three-jet Collision nebulizer and
air passing through the exposure chamber was collected
for sampling in an all-glass impinger (AGI) [21]. Titer of
the aerosolized agent collected in AGIs was determined
for each exposure by viral plaque assay. The actual in-
haled dose of EEEV was calculated based on the concen-
tration and volume of the AGI samples, the estimated
minute volume, and flow rate of the aerosol sampler
using the following formula:
Inhaled Dose ¼ C AGIð Þ x V AGIð Þ x MV=Q AGIð Þ
Where inhaled dose (PFU) is calculated based on: C,
the concentration (PFU/mL) of the virus sampled from
the AGI; V, the volume contained in the AGI sample
(mL); MV, the minute volume (mL/min) for each animal
estimated from Guyton’s formula; and Q, the flow rate
of the AGI sampler (mL/min).
Telemetry analysis
Marmoset body temperature was recorded using the
DataQuest A.R.T 4.1 system (DSI). The system was set
to collect data every five minutes, beginning 7 days prior
to aerosol exposure and continuing until day 28 post-
exposure or earlier if study endpoint criteria were met.
Statistical analysis was conducted as a Bayesian estima-
tion of the distribution of daytime body temperature for
each marmoset prior to aerosol challenge that was sub-
sequently used to compute a credible range for body
temperatures using SAS Markov chain Monte Carlo
simulation procedures (PROC MCMC). Data analysis in-
cluded temperature measurements that were compatible
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with life (i.e., ≤ 42 °C). The 99.7% credible range gener-
ated for each animal’s daytime body temperature was
analogous to an interval of ±3 standard deviations (SD)
for a normally distributed variable. All post-aerosol chal-
lenge temperature readings were compared to the ex-
pected temperature interval estimated for each animal.
Temperature measurements above the upper limit of the
estimated interval were noted as elevated and used to
compute fever summary statistics.
Observation, clinical evaluation, and study endpoint
criteria
Marmoset clinical observations began three days prior
to aerosol exposure for a baseline appearance and behav-
ior appraisal and continued minimally twice daily post-
exposure. Several factors were used when evaluating
clinical signs of disease for each marmoset. Clinical
observation parameters included: (1) neurological signs
(0 = normal; 1 = loss of coordination, 2 = occasional
tremors, 3 = loss of balance, 4 = frequent tremors/sei-
zures); (2) temperature (0 = normal, 1 = > 1 °C above
baseline, 2 = 2 °C above baseline, 3 = 3 °C above or below
baseline, 15 = 4 °C below baseline); (3) appearance (0 =
normal, 1 = reduced grooming, 2 = dull/rough coat or
ocular nasal discharge, 3 = lethargy, 4 = piloerection or
hunched up); (4) natural behavior (0 = normal, 1 = minor
changes, 2 = little peer interaction, less mobile, 3 = no
peer interaction, vocalization, or self-mutilation); and (5)
provoked behavior (0 = normal, 1 = subdued when not
stimulated, 2 = subdued when stimulated, 15 = unrespon-
sive/weak, pre-comatose). To further assess the health
status of the marmosets, animals were anesthetized
every three days for collection of weight and to conduct
a physical examination. During this time, blood samples
were collected for complete blood count (CBC) analysis.
White blood cell (WBC) counts were included in the
clinical scoring of the animals. Scoring criteria for WBC
were as follows: 0 = normal (0–10 K/μl); 1 = 10–12 K/μl;
2 = 12–14 K/μl; 3 = 14–20 K/μl; 4 = > 20 K/μl. In
addition, blood oxygen saturation was determined every
three days using a pulse oximeter. Study endpoint or
euthanasia criteria took into consideration the clinical
observation score, body temperature, and WBC results.
Animals with a total clinical score ≥15 were considered
to have reached a peak disease state and to have met the
pre-determined criteria for study endpoint; moribund ani-
mals that reached this score were humanely euthanized.
Plaque assay
Dissemination of infectious virus in blood and tissues
was assessed by plaque assay. Briefly, USAMRIID Vero
76 cells, derived from African Green monkey kidney
cells, were seeded on 6-well tissue culture plates and
grown to 90–95% confluence. Samples were serially
diluted in Hanks’ Balanced Saline Solution (HBSS). Cells
were infected with 0.1 mL of serially diluted samples per
well, in triplicate. Plates were incubated at 37 °C, 5%
CO2 for 1 h with gentle rocking every 15 min. After 1 h,
cells were overlaid with Eagle’s Basal Medium (BME)
(Gibco A15950DK) containing 0.6% agar supplemented
with 10% heat-inactivated FBS, 2% Penicillin/Strepto-
mycin (10,000 IU/mL and 10,000 μg/mL, respectively),
and further incubated for 24 h at 37 °C, 5% CO2. A sec-
ond agarose overlay, prepared as described above, con-
taining 5% neutral red vital stain (Gibco 02-0066DG)
was added to wells and further incubated for 18–24 h
for visualization of plaques and determination of viral
concentration in each sample (virus plaque forming
units [PFU] value).
Semi-quantitative RT-PCR
Viral RNA was detected by reverse-transcriptase polymer-
ase chain reaction (RT-PCR). Viral RNA from blood and
swab samples was isolated using QIAamp Viral RNA mini
kit (QIAGEN, Valencia, CA). RNA from tissue samples
was isolated using RNeasy mini-protect kit (QIAGEN,
Valencia, CA). Semi-quantitative RT-PCR was used for de-
tection of viral RNA from oral swab samples as well as
blood and tissue samples from the study marmosets. The
EEEV viral RNA assay was designed to amplify a portion
of nonstructural protein 1 (nsp1) of the Georgia 97 strain
of EEEV using the following primers and probe: EEEV
Forward 5′-TGCAAAgATGCTTTCC-3′, EEEV Reverse
5′-TCACCTGGTCTGTATCCA-3′, and a FAM (Carbo-
xyfluorescein) and TAMRA (Carboxytetramethylrhoda-
mine) dual-labeled TaqMan probe 5′-CAACGCAGGT
CACTGACAAT-3′. Quantification of viral RNA in sam-
ples was achieved by comparison of unknown blood and
tissue samples to an RNA standard generated from EEEV
FL93-939 virus, that is the same virus strain used for the
aerosol exposure of experimental animals. The standard
curve ranged from 5.0 × 107 (upper limit of detection
[ULOQ]) to 5.0 × 102 viral RNA copies (lower limit of de-
tection [LLOQ]). Repeated attempts to amplify virus
below the LLOQ failed to consistently and reliably dem-
onstrate amplification, thus the LLOQ was set at 5.0 × 102
viral RNA copies. Positive and negative extraction controls
were created by supplementing uninfected NHP blood
with a known amount of EEEV FL93-939 virus (5.0 × 104
viral genomic copies) and RNase-free water, respectively.
Pathology
Necropsies were performed on each marmoset under
BSL-3 conditions. Tissues were collected from all major
organs in the body for histopathological and immuno-
histochemical assessment. Tissues were immersion fixed
in 10% buffered formalin and held in biocontainment for
a minimum of 21 days. Tissues for histopathology
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underwent routine histologic processing, were embed-
ded in paraffin, sectioned, and stained with hematoxylin
and eosin. Immunohistochemistry was performed on all
tissue sections using a rabbit anti-Alphavirus (#1140)
antibody (1: 8000 dilution) and a commercial immuno-
peroxidase detection kit (EnVision System, Dako Corp.,
Carpinteria, CA). After pretreatment with a TRIS/EDTA
buffer (pH 9.0) at 97 °C for 30 min, primary and second-
ary antibodies were applied and the slides were incu-
bated with substrate-chromagen solution according to




To evaluate the common marmoset (Callithrix jacchus)
as an animal model of aerosolized EEEV infection, five
marmosets were challenged with increasing doses of
EEEV in a head-only aerosol exposure chamber and then
observed to determine how well the marmoset model
emulated human disease. The individual inhaled doses
obtained for each of the exposed marmosets were:
2.40 × 101 PFU, 1.15 × 103 PFU, 1.20 × 104 PFU, 9.76 ×
104 PFU and 7.95 × 105 PFU. The escalating doses of
aerosolized EEEV elicited various responses in the ani-
mals tested; one marmoset survived, three marmosets
became moribund and reached predefined study end-
point/euthanasia criteria (defined as a cumulative score
of ≥ 15 taking into consideration the clinical observation
score, body temperature, and WBC of each animal), and
one marmoset succumbed to disease. In addition to sur-
vival, clinical and physiological changes were assessed
and diagnostic tests were used to monitor blood and tis-
sue dissemination of the virus in the marmosets.
Clinical signs
Marmosets were observed for the development of clin-
ical signs indicative of EEEV disease in accordance with
the scoring system described in the Material and
Methods section. Briefly, clinical observation parameters
included neurological signs (e.g., loss of coordination,
tremors, or seizures), fever or hypothermia, appearance
(e.g., changes in coat/grooming, lethargy, hunched pos-
ture), natural behavior (e.g., reduced interaction with
peers or observers, vocalizations, reduced activity), and
provoked behavior (e.g., changes in response to stimula-
tion or pre-comatose posture). Subtle changes in the ap-
pearance and behavior of animals were observed as early
as day 2 following EEEV aerosol exposure, and by day 3,
most marmosets had presented with clinical signs, with
the exception of marmoset #1 (2.4 × 101 PFU) (Fig. 1).
Marmoset #1 (inhaled dose: 2.4 × 101 PFU) survived and
displayed minimal observable clinical changes, mainly
between days 4 and 12. Ruffled fur and reduced
grooming of marmoset #1 were the first visual signs of
infection to be noted in the daily observations. Survival
time following aerosol exposure was observed to be in-
versely proportional to the inhaled dose. Marmoset #2
(1.15 × 103 PFU) received an inhaled dose that resulted
in a prolonged study observation period (marmoset
reached euthanasia criteria on day 19 post-exposure).
Marmoset #3 received an intermediate dose of 1.2 × 104
PFU that corresponded to a survival profile observed to
fall between the lower and higher doses; the marmoset
reached euthanasia criteria on day 12 post-exposure.
Marmoset #4 (9.76 × 104 PFU), receiving an aerosol dose
approximately one half-log less than marmoset #5, dis-
played a similar, but more prolonged course of disease
than that of marmoset #5. The clinical scores for mar-
moset #4 were higher between days 3 and 4 and the ani-
mal reached euthanasia criteria by day 6, two days later
than marmoset #5. Marmoset #5, receiving the highest
dose of aerosolized EEEV (7.95 × 105 PFU) showed clin-
ical signs as early as day 2 following exposure and suc-
cumbed to the disease on day 4, displaying an
abbreviated disease course due to the severity of infec-
tion. Lethargy, decreased interaction, slight piloerection,
tremors, and lack of balance were noted in several of the
animals that became moribund and met euthanasia cri-
teria; these marmosets received higher inhaled doses of
EEEV. At later times in the disease course, marmosets
became more subdued in their behavior and response to
stimulation was absent, even when provoked.
The effect of EEEV exposure on marmoset body weight
was assessed. Considerable weight loss was observed be-
tween day −3 and study endpoint in marmoset #3 (1.2 ×
104 PFU) and marmoset #4 (9.76 × 104 PFU) with loss in
body weight of 6.25 and 13.3%, respectively (Fig. 2). The
rapid progression of disease into lethality observed for
marmoset #5, having received the highest EEEV dose, re-
sulted in a marginal decrease in weight between day −3
and day 4 post-exposure (endpoint). For doses below
1.2 × 104 PFU, a 4.02% weight increase was observed for
marmoset #2 and a modest 1.34% decrease for marmoset
#1. These results indicate that weight loss was observed to
be greater in marmosets that received higher aerosol
doses. In fact, the dose range encompassing marmosets #3
and #4 was the critical interface where clinical mani-
festations and body weight loss were most evident; these
results corroborate changes in weight that have been re-
ported for other species such as mice, hamsters, and
guinea pigs [15, 22, Erwin-Cohen, unpublished data].
The hematological changes occurring in marmosets
receiving distinct aerosol doses were next addressed. For
this purpose, CBCs were performed on samples col-
lected pre-exposure and then on days 3, 6, 9, 12, 15, 18,
21, 24, 27 and at study endpoint (Fig. 3). Marmosets that
received lower doses of EEEV initially displayed a
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decrease in WBCs on days 3 to 9 post-exposure (Fig. 3a).
Overall, an increase in total WBC count was observed in
marmosets that progressed through the disease course,
consistent with reports of leukocytosis in human cases
of EEEV infection (Fig. 3a). Sharp increases in WBCs
and neutrophils (a clear contributor to the overall in-
crease in WBCs) occurred during the peak days of clin-
ical disease (Fig. 3a and b, respectively) for marmosets
that received a lethal dose. It was noted that marmoset
#2 also displayed acute increases in WBCs and neutro-
phils on day 15, but the levels of both returned to pre-
exposure levels by days 15–18 as the animal became
moribund. The increase in the number of lymphocytes
(Fig. 3c) followed a trend similar to that of the neutro-
phils (Fig. 3b) for the marmosets receiving lethal aerosol
doses. A biphasic lymphocyte response was noted for
the surviving marmoset #1. A steady increase in mono-
cytes was noted in marmosets #2 and #3 over the course
of infection, though there was a sharp increase noted for
marmoset #2. The increase in monocytes observed for
marmoset #2 was most intense between days 9–18.
Likewise, monocytosis was observed for marmoset #1
(the lone surviving animal) between days 9 and 18, but
resolved thereafter until the end of study (Fig. 3d). In
Fig. 1 Clinical observation scores in marmosets with increasing doses of aerosolized EEEV. Clinical observation parameters included: (1) neurological
signs, (2) temperature, (3) appearance, (4) natural behavior, and (5) provoked behavior. Animal behavior was noted and the sum of the score for each
parameter was calculated. The values correspond to the highest score obtained for a marmoset per day
Fig. 2 Effect of aerosolized EEEV on total body weight of marmosets. Marmoset weights were recorded every third day during anesthetized physical
observation. Weight loss was most evident in marmosets #3 and #4. The disease course, including weight loss, for marmoset #2 followed a more
prolonged course, consistent with the lower inhaled dose of EEEV that the animal received. Marmoset #5 failed to show a meaningful decrease in
body weight since this animal succumbed to disease on day 4 post-exposure
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general, the number of platelets showed a downward
trend over the course of infection. The surviving mar-
moset #1 had a substantial drop in platelets between
days 3 and 9; however, this was resolved by the end of
the study (Fig. 3e). Mild thrombocytopenia has been ob-
served in cynos experimentally infected with a human
isolate of EEEV (strain V105-00210) [Burke, personal
communication]; however, this is the first observation of
thrombocytopenia in marmosets in response to EEEV
infection. No animal displayed signs of anemia during
the course of study; levels for hemoglobin, hematocrit,
and red blood cells (RBC) remained within normal levels
throughout the study (data not shown). The leukocytosis
observed in marmosets infected with EEEV agrees with
published reports of similar effects of EEEV infection in
humans [6, 7]. The normal hematological and serum
chemistry ranges in marmosets were established from
the USAMRIID colony of marmosets prior to the study
(Additional file 1: Table S1).
Fever onset and duration followed a dose-dependent
pattern (Fig. 4). With the exception of marmoset #1 that
received the lowest dose, all other marmosets developed
fever as defined by a temperature change that was 3 SD
over the average body temperature for that animal and
occurring on at least three consecutive readings (Fig. 4
and Table 1). Although marmoset #1 revealed sporadic
spikes in temperature resembling fever, those spikes did
not occur continuously (data not shown). This animal
was the only one that survived aerosol exposure until
the planned duration of the study. In marmosets receiv-
ing the highest EEEV doses (marmosets #4 and #5),
fever occurred earlier and had a shorter duration (see
Fig. 4d and e, and Table 1), and for lower-inhaled doses,
fever was more prolonged as was the course of the
Fig. 3 Hematological changes in marmosets after aerosolized EEEV challenge. The doses of EEEV to that the marmosets were exposed are
indicated in the bottom right of the figure. Grey areas over the graphs correspond to normal value ranges for marmosets. The graphs show the
results for (a) white blood cell counts, (b) neutrophils, (c) lymphocytes, (d) monocytes, and (e) platelets in the infected marmosets through time
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disease (see Fig. 4b and c, and Table 1). The common as-
pect for the marmosets that met euthanasia criteria was
an increase in body temperature (fever), at times consid-
erable, immediately followed by a noticeable drop in the
animal’s body temperature as the animal became mori-
bund (Fig. 4b-e). In contrast, the surviving marmoset
(marmoset #1) retained a steady body temperature
throughout the course of the study without onset of
fever. In the exposed marmosets, fever persisted for 25 h
to 122 h. Marmoset #2, which received the lowest lethal
aerosol dose of EEEV, exhibited the most prolonged
period of fever (Table 1). In all animals, fever peaked at
approximately 40 °C, except for marmoset #5 that
peaked at 43.6 °C.
Oxygen saturation levels in blood were also collected
to further evaluate the health status of the marmosets in
the study. These data were obtained using a pulse oxim-
eter (Fig. 5). Variation in oxygen saturation was more
evident in marmosets receiving intermediate doses of
EEEV aerosol (i.e., marmoset #3: 1.20 × 104 PFU and
marmoset #4: 9.76 × 104 PFU) in Fig. 5. The sharp
change in oxygen saturation observed for the marmosets
exposed to intermediate doses were not noted in those
animals receiving either the highest or the two lowest
EEEV doses. No dramatic changes in percent oxygen sat-
uration were noted in marmosets that received highest
and two lower doses of EEEV. Compared to pre-
exposure values (day −3), percent oxygen saturation de-
creased from 94% at day −3 pre-aerosol exposure to 86%
at study endpoint (day 12) for marmoset #3 (Fig. 5). A
similar drop was seen for marmoset #4 (9.76 × 104 PFU)
from 98% (day −3) to 87% (study endpoint, day 6).
Virus dissemination
The presence of virus in tissues, whole blood, and oral
swabs collected from infected marmosets was assessed
Fig. 4 Fever response in marmosets after EEEV aerosol challenge. Variation in body temperature is shown for (a) marmoset #1, (b) marmoset #2,
(c) marmoset #3, (d) marmoset #4 and (e) marmoset #5. Fever was determined by comparing baseline body temperatures of the marmosets with
temperatures measured after aerosol exposure. Baseline temperatures were collected every five minutes from as early as 7 days before challenge.
Telemetry collection continued after exposure until study endpoint (up to 28 days post-exposure). Average daily elevations in body temperature
and any residual temperature data above 3 SD were used to compute fever duration
Table 1 Summary of febrile response in marmosets exposed to increasing doses of aerosolized
Animal Inhaled Dose Fever onset Duration Fever Peak Temp Last Temp Taken Time of Death
ID (PFU) (day) (hr) (°C) (°C) (day post exposure)
1 2.40 × 101 N/A 0 N/A 36.0 28
2 1.15 × 103 10 122 40.1 31.4 19
3 1.2 × 104 8 64 39.8 34.2 12
4 9.76 × 104 3 53 40.6 36.1 6
5 7.95 × 105 2 25 43.6 37.5 4
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either by plaque assay and RT-PCR. Tissues were col-
lected from the marmosets at necropsy, while the blood
and oral swab samples were serially collected prior to
exposure and every 3 days following aerosol exposure at
physical examination while the marmosets were under
anesthesia. Infectious virus was found to be widely dis-
seminated in tissues of marmosets that received the
higher EEEV aerosol doses (marmosets #3 through #5)
(Table 2). Marmoset #1 received a non-lethal dose and
was the only animal with no detectable EEEV in tissues
by either plaque assay or RT-PCR (Table 2). Virus was
detected in brain by at least one of the detection
methods in all marmosets that received a lethal dose
(marmosets #2 through #5) (Table 2). The liver and kid-
ney had detectable levels (by at least one method) of
virus in the marmosets that received the three highest
EEEV doses (marmosets #3 through #5). EEEV was de-
tected in the mesenteric lymph node and heart of mar-
mosets receiving higher doses of aerosolized EEEV
(Table 2). Infectious virus was detected in the lungs by
plaque assay only in the marmoset that received the
highest inhaled dose of EEEV, suggesting that the virus
is rapidly cleared from the lungs during inhalational in-
fection (Table 2). EEEV was detected in the inguinal and
mandibular lymph nodes by both plaque assay and RT-
PCR in marmoset #3, an animal that received an inter-
mediate dose of EEEV and survived to day 12 post-
exposure. The adrenal gland was positive by both plaque
assay and RT-PCR in the marmoset that received the
highest dose.
When blood samples were assessed by plaque assay,
viremia was not detected in any animals at any time
point (data not shown). Only marmoset #1 tested posi-
tive for EEEV RNA in the blood by RT-PCR at days 9
and 12 post (Table 3). Oral swabs were also negative for
EEEV by either plaque assay or RT-PCR (data not
Fig. 5 Changes in blood oxygen saturation in the marmosets was
measured prior to and following exposure to aerosolized EEEV.
Blood oxygen saturation values were determined using a pulse
oximeter every 3 days while animals were under anesthesia for
physical examination
Table 2 Viral Plaque Assay and RT-PCR results in solid tissues from marmosets exposed to aerosolized EEEV























Salivary Gland - - - - 1.4E + 04 - - - - -
Adrenal Gland - - - - - - - - 1.2E + 04 +
Pancreas - - - - - - - - - -
Lung - - - - - - - - 2.0E + 04 -
Spleen - - - - - + - + - -
Axillary LN - - - - - - - + - -
Kidney - - - - - + 1.3E + 04 + 9.5E + 03 -
Brain - - - + 1.6E + 07 + 4.2E + 04 + - +
Heart - - - - - - 3.6E + 03 - - +
Liver - - - - - + 1.9E + 04 - - +
Inguinal LN - - - - 4.2E + 04 - - - - -
Mandibular LN - - - - 4.2E + 04 + - - 7.4E + 03 -
Tracheobronchial LN NT NT - - - + 5.0E + 04 - - +
Mesentric LN - - - - - - 7.3E + 04 - - +
Popliteal LN - - - - - + - - - -
NT no tissue
+ = positive assay result; − = negative assay result
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shown). Comparison of results between plaque assay
and RT-PCR should be approached with caution as dif-
ferences in sensitivity and sample recovery between
these two assays may help explain why some samples
are positive for one assay but not the other.
Pathology
No gross lesions were present at necropsy in any animal,
irrespective of dose or disease outcome. Histologic
evaluation revealed few changes between doses in the
animals that reached euthanasia criteria. Clinical disease
progressed similarly, but the observations varied tempor-
ally depending on the aerosol dose with the exception of
the observation of vasculitis. Vasculitis was apparent in
marmosets that received doses greater than 1.0 × 104
PFU. The histologic changes included acute to subacute
meningoencephalitis (Fig. 6a) with neuronal necrosis
and prominent vasculitis (Fig. 6b) present within the
brain of marmosets infected at higher doses (>1.0 × 104
PFU). The surviving marmoset did not have any histo-
logic changes present. Of those with histologic lesions,
the portions of the brain most severely affected were the
frontal cortex, corpus striatum, thalamus; mesencephalon,
pons, medulla oblongata, and cerebellum. The meningo-
encephalitis consisted of infiltration of mononuclear inflam-
matory cells with high numbers of neutrophils. Additional
changes described included neuronal cell death (Fig. 6c and
d), gliosis, satellitosis, edema, and vasculitis. Hemorrhage
was occasionally present. Table 4 summarizes the patho-
logical findings observed in the EEEV-infected marmosets.
Presence of EEEV in select tissues was demonstrated
using immunohistochemistry (IHC). Positive IHC stain-
ing for EEEV antigen was observed in neurons within
the brain (Fig. 7a) and the retina (Fig. 7b). Regions of
brain with strongest IHC labeling were the frontal cor-
tex, corpus striatum, thalamus, mesencephalon, and
pons. Other tissues with positive IHC staining included
macrophages/dendritic cells within the mandibular and
axillary lymph nodes, interstitial cells of the ovary, and
cells of the inner ear (data not shown). Nasal turbinates,
nasal septum, and tooth pulp were also examined but
were negative for the presence of viral antigen by IHC
staining. No histologic changes were noted in the retina,
despite positive IHC antigen staining (Tables 4 and 5).
Discussion
New World alphaviruses represent a recognized biological
threat that can be intentionally delivered by aerosol; new
vaccines and therapeutics that are being developed must
be tested for efficacy against alphavirus inhalation expos-
ure [23]. The purpose of the present work was to investi-
gate the common marmoset (Callithrix jacchus) as a
model of inhalational EEEV disease. There is an acknowl-
edged need within the defense research community to
characterize a variety of animal models of alphavirus infec-
tion with respect to FDA requirements under the Animal
Rule for licensure of vaccines or therapeutics for patho-
gens for which human efficacy trials are not feasible or
ethical. Furthermore, there is a need to understand the
pathology of multiple serotypes of alphaviruses, particu-
larly VEEV and EEEV, in multiple animal models that re-
capitulate human disease as closely as possible. [8, 13, 14].
Several animal species have previously been examined as
models of EEEV infection including mice, hamsters,
guinea pigs, and macaques; however, no single model pre-
sents an ideal candidate to recapitulate human disease for
medical countermeasure testing.
Mice and hamsters are highly sensitive inhalation
models of alphavirus disease, yet the vascular manifest-
ation that is usually fatal in humans represents a shortfall
in the murine model as mice do not develop perivascular
infiltrates and only minimal encephalitis in the brain,
while the fulminant course of disease and rapid time to
death is a limitation in the utility of the hamster ([15, 24]
Erwin-Cohen, personal communication]). South American
strains of EEEV appear to produce a less virulent form of
disease in humans than do North American strains [25];
experiments to characterize the guinea pig model of EEEV
infection (with both North and South American strains)
have demonstrated some characteristics that are consist-
ent with human disease, such as fever, lethargy, and path-
ology of neuroinvasion [22]. Guinea pigs also demonstrate
some inconsistent characteristics that limit the utility of
the model; for example, aerosol infection in guinea pigs
produces similar lethal susceptibility to either South
American or North American strains of EEEV [22], in
contrast to what has been observed for human EEEV in-
fection. These results indicate species-specific differences
in host-pathogen interactions. The marmoset was demon-
strated to respond to intranasal infection with South
American and North American strains in a manner that is
similar to human disease with regard to differential sus-
ceptibility and thus warranted further investigation of this
species as model of inhalational EEEV infection [11].






−3 3 4 6 9 12 15 17 18 19 21 24 27
1 (2.40 × 101) - - - - + + - - - - - - -
2 (1.15 × 103) - - ND - - - - - - -
3 (1.20 × 104) - - ND - - -
4 (9.76 × 104) - - ND -
5 (7.95 × 105) - - ND
ND Not done
+ = positive PCR result; − = negative PCR result
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The effect of inhalational EEEV infection has been
assessed in both rhesus and cynomolgus macaque nonhu-
man primate species and in equine models [17, 26].
Nathanson and colleagues infected juvenile rhesus ma-
caques with a North American strain of EEEV via the intra-
nasal route and produced fatal encephalitis [26]. However,
further characterization of the rhesus model with adult pri-
mates or using the aerosol route of infection has never been
addressed. In their characterization of the cynomolgus ma-
caque as a model of aerosolized EEEV, Reed et al. [17] de-
scribed the clinical disease course in cynos that had been
exposed to two high doses of aerosolized North American
EEEV strain FL91-4679 that differed by only log0.5. Reed
observed signs consistent with human infection including
fever, increased heart rate, and leukocytosis, but also noted
additional features of the EEEV disease in cynos that were
inconsistent with human infection including elevated liver
enzymes and serum markers of liver damage [17].
The report on the common marmoset comparing viru-
lence of intranasal infections between North American
(NA) and South American (SA) strains of EEEV (re-classi-
fied as Madariaga virus) was promising as comparable
responses to humans were found in the marmoset model
[11]. The fact that in this study marmosets developed
vasculitis and have previously been reported to produce
neutralizing antibodies following infections with low
Fig. 6 Histopathology following exposure to aerosolized EEEV. a Examination of the frontal cortex of the brain revealed the presence of multifocal
meningoencephalitis with hemorrhage (HE; magnification, 4×). b Blood vessel in frontal cortex displayed vasculitis with perivascular hemorrhage
(arrow) (HE; magnification, 20×). c In the corpus striatum, two neurons (arrows) showed hypereosinophilic perikaryon (cytoplasm) suggesting necrosis.
Vasculitis (V) with perivascular hemorrhage was seen in an adjacent vessel and gliosis (asterisk) in the surrounding neuropil (HE; magnification, 40×). d
In the pons, three centrally located neurons (arrows) were observed that were shrunken and angular with hypereosinophilic perikaryon and deeply
basophilic (hyperchromatic) nuclei (HE; magnification, 60×). Images are from marmoset #4 exposed to 9.76 × 104 PFU of EEEV








Meningoencephalitis Vasculitis Retinitis Vasculitis
1 2.40 × 101 28 a - - - -
2 1.15 × 103 19 ++ - - -
3 1.2 × 104 12 +++ +++ - -
4 9.76 × 104 6 ++ ++ - -
5 7.95 × 105 4 b +++ +++ - -
a = Survivor, b = Succumbed to disease
+ =mildly present, ++ =moderately present, +++ = strongly/markedly present
Porter et al. Virology Journal  (2017) 14:25 Page 11 of 15
virulence alphavirus strains was interpreted as a promising
indication of this model as being suited for inhalational
studies. Collectively, these factors prompted us to evaluate
the marmoset for its suitability as a model of inhalational
EEEV disease.
To determine the effect of the aerosol dose on the in-
fectivity and disease development and estimate the med-
ial lethal aerosolized dose of EEEV for the marmoset,
inhaled doses ranging from 2.4 × 101 PFU to 7.95 × 105
PFU were tested. Markers of EEEV infection and disease
were observed. As the dose increased, so too did the se-
verity of the clinical disease course; marmosets reached
euthanasia criteria progressively earlier and displayed a
more abbreviated list of clinical signs and symptoms, re-
vealing the dose-dependent nature of EEE disease mani-
festation. A gradient of disease severity was observed
within the lethal doses. Marmosets receiving the two
highest doses of EEEV succumbed to disease by days 4
and 6, respectively. This dose range revealed a similar ef-
fect as that observed when marmosets were exposed by
the intranasal route with 1.0 × 106 PFU of the EEEV
FL93-939 strain [11]. In Adams’ work, the time of death
and the host responses observed were similar to what
we observed in the present study [11]. However, in our
study, marmosets exposed to lower doses of EEEV dis-
played a protracted time to death, and the surviving
marmoset exposed to the lowest aerosol dose remained
nearly asymptomatic throughout the course of the study.
The responses of the surviving marmoset more closely
resembled those of marmosets exposed intranasally to
the SA strain of EEEV (Madariaga virus) in Adams’
work; suggesting a dose threshold for NA strain toxicity
that responds similarly to high intranasal doses of the
less virulent SA strain (Madariaga virus) [11]. From the
survival and clinical disease results that were observed
in the present study, the median lethal aerosol dose in
marmosets was estimated to be 2.05 × 102 PFU.
Loss of body weight was demonstrated to be a factor in
the disease pathology of intranasal EEEV infection in mar-
mosets [11]. Loss of body weight has also been demon-
strated in rodent models of EEEV infection but has never
been demonstrated to be altered significantly in larger ani-
mal species such as macaques or humans [6, 15, 17]. We
observed a loss of body weight between day −3 and study
endpoint in response to aerosolized EEEV for marmosets
#3 and #4 (1.2 × 104 PFU and 9.76 × 104 PFU, respectively).
Infection with doses below this range either had no effect
on body weight or the marmoset gained weight, regardless
Fig. 7 Immunohistochemistry analysis for marmosets exposed to
aerosolized EEEV. The image in Panel a from the pons reveals
widespread positive antigen staining of neurons in the brain,
indicating the presence of EEEV viral RNA(immunohistochemistry;
magnification, 40×). Panel b, immunohistochemical staining for the
presence of antigen in the retina of marmoset #4. Depicted from the
top of the image toward the bottom are: inner limiting membrane,
optic fiber layer, ganglion cell layer, inner plexiform layer, inner nuclear
layer, outer plexiform layer, outer nuclear layer, and external limiting
membrane. The photo receptor layer appears predominantly negative
(bottom of image) and the pigment epithelium is barely present in the
image. Both images are from marmoset #4 exposed to 9.76 × 104 PFU
of EEEV
Table 5 EEEV Immunohistochemistry Results for Marmosets challenged with EEEV by the aerosol route
Marmoset Inhaled Dose (PFU) Time to Death
Postexposure
Brain Retina
1 2.40 × 101 28 a - -
2 1.15 × 103 19 + -
3 1.2 × 104 12 +++ +
4 9.76 × 104 6 +++ +++
5 7.95 × 105 4 b +++ -
a = Survivor, b = Succumbed to disease
+ =mildly present, ++ =moderately present, +++ = strongly/markedly present
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of whether the animal developed clinical disease leading to
euthanasia or not, indicating that the disease produced by
lower doses was insufficient to cause observable weight
loss. Marmoset #4 had a 4.2% decrease in body weight be-
tween day 3 and day 4 (animal found dead) post-exposure..
The results of the present study are consistent with Adams’
report of weight loss observed in marmosets exposed intra-
nasallyintransally with the EEEV FL93-939 NA strain at
1.0 × 106 PFU [11]. Challenge with the SA strain of EEEV
in Adams’ study resembled the results observed for marmo-
set #2 receiving a lower dose of NA EEEV strain (1.15 × 103
PFU). Because we covered a wider dose range of EEEV
doses in our median lethal dose study and possibly due to
the use of a different route of exposure, we were able to
capture differential effects on weight not previously ob-
served before for the same EEEV strain [11].
Marmosets exposed to the higher doses of EEEV
(≥9.76 × 104 PFU) were noted to have developed disease
and died roughly 2–3 days following the time of fever
onset. This observation is in agreement with Adams’
work as well as with previous data from cynomolgus ma-
caques [11, 17]. Rhesus macaques have also been ex-
posed to EEEV but displayed a more extended survival
time following fever onset [27]. The delayed effect on
time to death in the rhesus macaque model was also ob-
served in our study, but only for marmosets that were
exposed to the lower EEEV doses. These differences in
the more prolonged time to death from fever onset for
the rhesus may represent a species difference or be a re-
flection of distinct properties of the viral strains used as
well as conditions of viral stock preparation and stability
[27]. In the intermediate inhaled doses of EEEV in the
marmosets, it was noticed that there was an increase in
nocturnal activity for marmoset #2 at day 6 and for mar-
moset #4 at day 5 (data not shown); again, showing that
within the “intermediate” range of inhaled doses, a more
clearly traceable pattern of EEEV-driven effects could be
detected. Interestingly, effects on blood oxygen satur-
ation were more noticeable in this intermediate range,
where weight loss was also considerably affected. A de-
crease in oxygen saturation levels in the blood has been
previously shown in human influenza cases to reflect on-
going inflammatory responses and those results corre-
lated with body weight loss, body temperature changes,
and development of lung pathology [28]. The observed
depression in oxygen saturation levels in the marmosets
may also signal inflammatory responses captured in the
animals within these intermediate EEEV aerosol doses.
Although EEEV disease progressed on an altered time
course dependent on the aerosol dose, once animals de-
veloped clinical disease, the pathological changes were
similar between marmosets exposed to increasing in-
haled doses with the exception of observed vasculitis.
Vasculitis was present in marmosets that received doses
greater than 1.0 × 104 PFU, suggesting that it may a
dose-related phenomenon. Vasculitis is an important
pathological feature of human EEEV disease and factors
into the importance of not only characterizing an animal
model that will develop vasculitis, but provides insight
into the aerosol dose required to mimic the disease
course in humans. Therefore, aerosol doses greater than
1.0 × 104 PFU should be considered when using the mar-
moset as a disease model for aerosolized EEEV. Menin-
goencephalitis was also noted in our marmosets, and is
consistent with autopsy observations made for fatal hu-
man EEEV cases [29]. We observed positive antigen
staining is the pons and thalamus regions of the brain
from several of the marmosets; this observation of in-
volvement of specific areas of the brain is consistent
with reports of EEEV-induced signaling anomalies in the
basal ganglia, brainstem, and thalamus from magnetic
resonance imaging (MRI) in both severe non-fatal and
fatal human infections [30–32].
Viremia was not detected in the blood by plaque assay
at any time point, but viral genomic RNA was detected
by RT-PCR at days 9 and 12 post aerosol exposure in
the survivor marmoset receiving the lowest inhaled dose
(#1). Expression of EEEV has been shown to be re-
stricted to myeloid cells due to binding of microRNA
miR-142-3p at three conserved target sites within the 3′
UTR of the EEEV genome, which serves to functionally
block viral replication in cell types other than myeloid
cells [33, 34]. Overall, our data are in agreement with
previous work in marmosets that showed no viremia de-
veloped at a high dose with the NA strain of EEEV but
viremia was detected when the marmosets were infected
intranasally with the SA strain (now re-classified as
Madariaga virus) [11]. It is possible that the cell-type
constraints found in EEEV due to binding of miR142-3p
in a conserved region of the 3′ UTR do not occur in
Madariaga virus.
The main hematological change reported for EEEV in-
fection in humans and animal models is leukocytosis late
in infection, reflecting in great part the induction of gran-
ulocytes [6, 15, 17]. Not only were general increases in
white blood cells observed but also increases in absolute
numbers of neutrophils, lymphocytes, and monocytes.
Interestingly, monocytes have been shown to be refractory
to EEEV infection, with a possible exception of an immor-
talized monocytic cell line pre-treated with a mitogen
[35–37]. Outside of the known resistance of monocytes to
EEEV infection, these cells, along with lymphocytes, were
induced by EEEV in our work, even at non-lethal aerosol
doses, underscoring their role in modulating EEEV infec-
tion. In addition, a downward trend in the number of
platelets was observed after EEEV exposure, although it is
not as conclusive for the survivor. The observation of
thrombocytopenia in the marmosets that succumbed to
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disease is in agreement with the human disease course of se-
vere EEEV infection [38]. Platelet depletion has been previ-
ously associated with the increasing development of
vasculitis and potential coagulopathies. The hematology data
from the marmosets therefore describes an early initiated
neutrophilic response followed by a lymphocytic response in
the acute phase and culminating with monocytosis; this ob-
servation was more evident in marmosets receiving lower
doses of the virus. Because the high-dosed animals did not
live long enough for the body to fully respond with monocy-
tosis, this appears to be a dose-related event, where lower
doses may allow the animal to live long enough to mount a
robust immune response that includes monocytosis.
Limitations to the study include the small number of
animals tested to estimate the median lethal dose; how-
ever, the clinical, hematologic, and pathology data are con-
sistent with reports from other nonhuman models of
infection and thus support the use of the marmoset as a
novel aerosol model of inhalation EEEV for countermeas-
ure efficacy testing. Follow on studies will build upon the
work described herein to further refine the median lethal
dose with larger numbers of animals to achieve statistical
significance, as well as investigate the temporal changes in
disease pathology.
Conclusion
This work has evaluated the clinical and pathological ef-
fects of aerosolized EEEV in the common marmoset and
estimated the median lethal dose for aerosolized EEEV.
The marmoset has now been shown to be a promising
animal model for both the intranasal and aerosol routes of
EEEV encephalitic disease. We have demonstrated the
pathological effects of EEEV disease over a range of doses
and describe disease markers that can used with the
model for both therapeutic and prophylactic studies. The
results demonstrate that the marmoset is an animal model
suitable for emulation of human EEEV disease in the de-
velopment of medical countermeasures.
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